

**The YODA Project**  
**Research Proposal Due Diligence Assessment**

<b>Part 1: General Information</b>	
<b>YODA Project (Protocol) ID:</b>	2021-4849
<b>Date:</b>	25 January 2022
<b>Product Name:</b>	Canagliflozin/Macitentan
<b>Therapeutic Area:</b>	Metabolism / Pulmonary Hypertension
<b>Product Class:</b>	Endothelin receptor antagonist SGLT-2 inhibitor
<b>Condition(s) Studied:</b>	Type 2 Diabetes Mellitus/ Symptomatic Pulmonary Arterial Hypertension
<b>Protocol Number(s) and Title(s):</b>	<p><b>NCT00968812 - 28431754DIA3009</b> - A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus</p> <p><b>NCT00660179 - AC-055-302</b> - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension</p>
<b>Part 2: Data Availability</b>	
<b>Question:</b>	<b>Response:</b>
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments: N/A	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments: N/A	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments: N/A	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments: N/A	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments: N/A	
<b>Part 3: Data Availability Summary</b>	
Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.	Yes
<b>Part 4: Proposal Review</b>	
<b>Question:</b>	<b>Response:</b>
Summary-level CSR data is appropriate for the proposed analysis.	No

**The YODA Project**  
**Research Proposal Due Diligence Assessment**

Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments: HbA1c is not collected in the AC-055-302 study	